Quince Therapeutics Inc. Common Stock (QNCX)
Stock · NASDAQ · Health Care
$32.03as of 10/16/2026
Price chart
Active signals
QNCX Signal Track Record
How signals performed across all stocks →What QNCX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 28 | -3.5% | 39% | September 8, 2026 |
| Bollinger Band Breakout | 15 | 0.0% | 40% | July 29, 2026 |
| Volume Spike | 5 | +20.9% | 60% | October 2, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -4.2% | 50% | June 23, 2025 |
| Any 20-session window (baseline) | -4.9% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About QNCX
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutation…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 38
- Website
- quincetx.com/
Fundamentals
- 1-day range
- $29.84$37
- Market cap
- $30.04M
- P/E (trailing)
- —
- P/E (forward)
- -6.78
- EPS (trailing)
- $-125.71
- Dividend yield
- —
- Beta
- 1.80
- Avg. volume
- 30.0K
Forecasts
8 analyst ratings
Quince Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- QNCXQuince Therapeutics Inc. Common Stock$32.03▼ 3.61%Market cap $30.04MP/E —$15.1$910
- CVMCel-Sci Corporation Common Stock$1.79▲ 2.87%Market cap $28.14MP/E —$0.89$10.24
- ESLAEstrella Immunopharma Inc. Common Stock$0.43▼ 19.63%Market cap $32.10MP/E —$0.295$3.15
- ENGNWenGene Therapeutics Inc. Warrants$0.17▲ 1.19%Market cap $33.75MP/E —$0.1113$4.2
- ALGSAligos Therapeutics Inc. Common Stock$4.86▼ 9.83%Market cap $34.10MP/E —$3.98$13.69
- EVAXEvaxion A/S American Depositary Share$2.83▲ 1.07%Market cap $24.98MP/E —$2.72$12.15
- DYAIDyadic International Inc. Common Stock$0.41▼ 2.38%Market cap $37.17MP/E —$0.3401$1.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QNCX Quince Therapeutics Inc. Common Stock | $30.04M | — | $32.03 | ▼ 3.61% | $15.1$910 |
| CVM Cel-Sci Corporation Common Stock | $28.14M | — | $1.79 | ▲ 2.87% | $0.89$10.24 |
| ESLA Estrella Immunopharma Inc. Common Stock | $32.10M | — | $0.43 | ▼ 19.63% | $0.295$3.15 |
| ENGNW enGene Therapeutics Inc. Warrants | $33.75M | — | $0.17 | ▲ 1.19% | $0.1113$4.2 |
| ALGS Aligos Therapeutics Inc. Common Stock | $34.10M | — | $4.86 | ▼ 9.83% | $3.98$13.69 |
| EVAX Evaxion A/S American Depositary Share | $24.98M | — | $2.83 | ▲ 1.07% | $2.72$12.15 |
| DYAI Dyadic International Inc. Common Stock | $37.17M | — | $0.41 | ▼ 2.38% | $0.3401$1.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Quince Therapeutics Announces Appointment Of Brigette Roberts As CEO, John Militello As CFO, And Keith Fandrick As COO; CEO Dirk Thye And COO Brendan Hannah Resignbenzinga · 10/9/2026
- Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst callsYahoo · 9/24/2026
- This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · 9/24/2026
- Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70Benzinga · 9/24/2026
- Netflix downgraded, SanDisk initiated: Wall Street's top analyst callsYahoo · 9/22/2026
- Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price TargetBenzinga · 9/22/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 9/22/2026
- Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026Yahoo · 9/17/2026
Insider Activity
Insider Actions →- Lamond David · June 11, 2026 · Grant2.7K
- Christopher J. Senner · June 11, 2026 · Grant2.7K
- Roberts Brigette · May 18, 2026 · Grant6.84M
- Roberts Brigette · May 18, 2026 · Grant2.07M
- Roberts Brigette · May 18, 2026 · Grant133.6K
- Roberts Brigette · May 18, 2026 · Grant362.1K
- Roberts Brigette · May 18, 2026 · Grant69.3K
- Roberts Brigette · May 18, 2026 · Grant124.8K
- Roberts Brigette · May 18, 2026 · Grant228.9K
- Roberts Brigette · May 18, 2026 · Grant34.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70
Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.